Filter Results:
(923)
Show Results For
- All HBS Web
(1,277)
- People (5)
- News (171)
- Research (923)
- Events (6)
- Multimedia (12)
- Faculty Publications (755)
Show Results For
- All HBS Web
(1,277)
- People (5)
- News (171)
- Research (923)
- Events (6)
- Multimedia (12)
- Faculty Publications (755)
Sort by
- 19 Aug 2002
- Research & Ideas
Here Comes Internet2—Time to Shed Dot Vertigo
The same DVD would take approximately twenty-five hours to download via a standard DSL/cable line (and 170 hours—or more than seven days—via a 56K modem). Genomics and pharmaceuticals are other research arenas that should benefit from the... View Details
Keywords: by Martha Lagace
- 13 Jan 2009
- First Look
First Look: January 13, 2009
and regulation of clinical trials, managerial challenges related to pharmaceutical product testing, and current debates regarding prescription drug safety. Since clinical testing takes between five and seven years, and consumes up to 70... View Details
Keywords: Martha Lagace
- 30 Oct 2007
- First Look
First Look: October 30, 2007
Changing Context of Pharmaceutical Risk Mitigation Author:Arthur A. Daemmrich Periodical:Pharmacy in History 49, no. 2 (2007): 61-75 Abstract In the wake of Vioxx, Avandia, and other recent prominent cases of drugs found to cause side... View Details
Keywords: Sean Silverthorne
- 05 Jan 2011
- Op-Ed
Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress
In light of the latest developments of the on-again, off-again, on-again government funding of human embryonic stem-cell research, it is time to consider the devastating implications of this chaotic funding environment. And to do that, one needs to understand how a... View Details
- 01 Jun 2009
- Lessons from the Classroom
The Challenges of Investing in Science-Based Innovation
In economic downtimes, businesses are apt to cut R&D projects that don't promise a speedy return on investment. But take a cue from smart science-based businesses, which view the recession as an opportunity to stoke up research and innovation for long-term... View Details
- November 2006
- Case
Competitive Headaches (A): The Analgesic Wars
By: Dennis A. Yao
Addresses the problem of competing with a me-too consumer product. Focuses on Bristol-Meyers' 1975 strategy for introducing a competitor to Tylenol in the analgesic market. View Details
- November 1999
- Teaching Note
drugstore.com TN
By: Richard L. Nolan
Teaching Note for (9-300-036). View Details
- 26 Apr 2011
- Op-Ed
HBS Faculty Comment on Environmental Issues for Earth Day
Earth Day focuses the world's attention on the both the dangers and opportunities facing the planet. But sustainability and the intersection between business and the environment are issues that need to be addressed all the time, as cities grow, resources diminish, and... View Details
- 18 Aug 2017
- Op-Ed
Op-Ed: Courageous Leader Triggers a Moral Revolt of CEOs Against Trump
actions was not without risk for the CEOs and their companies” While many CEOs prefer to stay under the radar and avoid public scrutiny, Ken Frazier led the way with his example. As the chair of PhRMA, the pharmaceutical manufacturers... View Details
Keywords: by Bill George
- 20 May 2013
- Op-Ed
Making America an Industrial Powerhouse Again
talent pool in the US biomedical field that is second to none. And the only way to get that talent is for companies-both domestic and foreign-to do their R&D here. That's why pharmaceutical and biotechnology companies from around the... View Details
- 23 May 2000
- Research & Ideas
Minding the Muse: The Impact of Downsizing on Corporate Creativity
pharmaceutical firms that rely on creativity," she says. "Today's fast-changing global markets place increased pressure on companies of every kind to continuously create new products, services, and competitive strategies if they... View Details
Keywords: by Peter K. Jacobs
- July 2014 (Revised February 2015)
- Teaching Note
Johnson & Johnson: The Promotion of Wellness
By: John A. Quelch
The chief medical officer of Johnson & Johnson (J & J) is reflecting on forty years of sustained efforts by the company to improve employee wellness. The case reviews J & J's multiple wellness initiatives and efforts to measure their effectiveness. It also invites... View Details
Keywords: Empoylee Wellness Programs; Human Resource Management; Corporate Management Strategy; Employee Engagement; Human Resources; Management; Organizations; Performance; Personal Development and Career; Programs; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; North and Central America; Europe; Asia
- 06 Aug 2001
- Research & Ideas
Go Global—or No? Can You Make the Case?
Remember, we don't yet have the capability to serve the chemical and pharmaceutical industries here. There are still only 38 of us, and I estimate that building the support infrastructure we need just for domestic expansion could cost as... View Details
Keywords: by Walter Kuemmerle
- 05 Mar 2001
- What Do You Think?
Fine Coupling: Can Human Resource Management Learn from Supply Chain Management?
Productivity will improve as the alternation of job assignments eliminates the 'indispensable' worker." Connie Luthy says, "I have practiced 'Just-In-Time' hiring ... in the pharmaceutical industry.... I have advised my client... View Details
Keywords: by James Heskett
- 26 Apr 2023
- Cold Call Podcast
How Martine Rothblatt Started a Company to Save Her Daughter
- Research Summary
Overview
I am interested in the individual experience of learning in organizational settings, particularly how employees learn to learn from the challenging work they do.
I am currently researching the role of reflection for raising awareness of learning opportunities that... View Details
- January 2023
- Teaching Note
The Opioid Settlement and Executive Pay at AmerisourceBergen
By: Suraj Srinivasan and Li-Kuan Ni
Teaching Note for HBS Case No 122-014. In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged... View Details
Keywords: Opioids; Shareholder Activism; Investment Activism; Corporate Accountability; Corporate Governance; Governance Compliance; Governance Controls; Executive Compensation; Risk Management; Corporate Social Responsibility and Impact; Business and Shareholder Relations; Business and Stakeholder Relations; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; West Virginia; Tennessee; Ohio; Pennsylvania
- Article
Internal Deadlines, Drug Approvals, and Safety Problems
By: Lauren Cohen, Umit Gurun and Danielle Li
Absent explicit quotas, incentives, reporting, or fiscal year-end motives, drug approvals around the world surge in December, at month-ends, and before respective major national holidays. Drugs approved before these informal deadlines are associated with significantly... View Details
Keywords: Health; Economics; Government and Politics; Innovation and Invention; Research; Science; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry
Cohen, Lauren, Umit Gurun, and Danielle Li. "Internal Deadlines, Drug Approvals, and Safety Problems." American Economic Review: Insights 3, no. 1 (March 2021): 67–82.
- February 1999
- Teaching Note
Wegmans Food Markets: Diabetes Counseling TN
By: David E. Bell
Teaching Note for (9-599-057). View Details
- 05 May 2015
- First Look
First Look: May 5
methodology using a novel dataset developed with the division of a large pharmaceutical firm. The dataset consists of all components in the enterprise architecture, the observed dependencies between them, and estimated costs of change for... View Details
Keywords: Carmen Nobel